# US 2015/0031694 A1 · Antimicrobial agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031694 A1
- Document ID: US20150031694A1
- Status: Published application
- Kind: A1
- Application number: 14/386,718
- Filed: 2013-03-21
- Published: 2015-01-29
- Earliest claimed: 2012-03-21
- Assignees: Rutgers, The State University of New Jersey
- Applicants: Rutgers, the State University of New Jersey
- Inventors: Edmond J. LaVoie; Ajit Parhi; Yongzheng Zhang; Daniel S. Pilch; Malvika Kaul
- Web page: https://patentgrep.com/patent/US20150031694A1

## CPC

- C07D 277/64: with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- A61P 31/04: Antibacterial agents
- C07D 263/32: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 263/34: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 263/56: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D 277/24: Radicals substituted by oxygen atoms
- C07D 277/30: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 513/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides compounds of formula (I): wherein R1-R7 and W have any of the values defined in the specification, and salts thereof. The compounds have good solubility and are useful for treating bacterial infections.

## Claims

### Claim 1

A compound of formula (I):
wherein:
R1 is hydrogen or 1, 2 or 3 optional substituents;
W is CRa, or N;
Ra is absent, hydrogen, or an optional substituent, R2 is hydrogen, methyl, or fluoro, and R2′ is hydrogen, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C8)cycloalkyl, aryl, or 5-6 membered heterocyclyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heterocyclyl may be optionally substituted with one or more Rb;
or Ra and R2 taken together are —CH2—, —CH2—CH2—, —O—, —O—CH2—, —CH2O—, —O—CH2—CH2—, or —CH2—CH2—O—;
or Ra is absent, hydrogen or an optional substituent, and R2′ taken together with R2 is cyclopropyl, cyclobutyl, azetidine, or ═CH—N(Rc)2; wherein the cyclopropyl, cyclobutyl, and azetidine can optionally be substituted with (C1-C6)alkyl;
R3 is (Alk1)m-(Z)p-(Alk2)n-Q;
Z is —O—, —S—, —S(O)—, —SO2—, —NH—, —N(CH3)—, —N(CH2CH3)—, —C(═O)—, —OC(═O)—, —C(═O)O—, or an optionally substituted divalent monocyclic carbocycle or heterocyclic radical having 3 to 6 ring atoms, or an optionally substituted divalent bicyclic heterocyclic radical having 5 to 10 ring atoms;
Alk1 is optionally substituted (C1-C6)alkylene, (C2-C6)alkenylene, or (C1-C6)alkynylene radical, which may optionally terminate with or be interrupted by —O—, —S—, —S(O)—, —SO2—, —NH—, —N(CH3)—, —N(CH2CH3)—;
Alk2 is optionally substituted (C1-C6)alkylene, (C2-C6)alkenylene, or (C1-C6)alkynylene radical, which may optionally terminate with or be interrupted by —O—, —S—, —S(O)—, —SO2—, —NH—, —N(CH3)—, —N(CH2CH3)—;
Q is hydrogen, halo, cyano, or hydroxyl, or an optionally substituted monocyclic carbocyclic or heterocyclic radical having 3 to 7 ring atoms, or an optionally substituted bicyclic heterocyclic radical having 5 to 10 ring atoms;
the bond represented by ---- is a double bond, R4 is hydrogen or methyl, and R5 is absent; or the bond represented by ---- is a single double bond, R4 is H, optionally substituted monocyclic carbocycle, or heterocyclic radical having 3 to 6 ring atoms, and R5 is hydrogen; wherein each optionally substituted monocyclic carbocycle, or heterocyclic radical having 3 to 6 ring atoms of R4 is optionally substituted with one or more (e.g. 1, 2, or 3) substituents independently selected from (C1-C6)alkoxy, halo, hydroxy, cyano, nitro, amino, methylamino, dimethylamino, carboxy, (C1-C6)alkoxycarbonyl, aminocarbonyl, (C1-C6)alkanoylamino, or tetrazole;
R6 and R7 are each independently hydrogen, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, or a heterocyclic radical having 3 to 6 ring atoms, or R6 and R7 together with the nitrogen to which they are attached form a 5 or 6 membered heterocyclic ring, which ring is optionally substituted with one or more groups independently selected from (C1-C6)alkyl; wherein any (C1-C6)alkyl of R6 and R7 is optionally substituted with one or more (e.g. 1, 2, or 3) substituents independently selected from (C1-C6)alkoxy, halo, hydroxy, cyano, nitro, amino, methylamino, dimethylamino, oxo (═O), carboxy, (C1-C6)alkoxycarbonyl, aminocarbonyl, (C1-C6)alkanoylamino, aryl, or tetrazole; and wherein any aryl or heterocyclic radical having 3 to 6 ring atoms of R6 and R7 is optionally substituted with one or more (e.g. 1, 2, or 3) substituents independently selected from (C1-C6)alkyl, (C1-C6)alkoxy, halo, trifluoromethyl, trifluoromethoxy, hydroxy, cyano, nitro, tetrazole, carboxy, (C1-C6)alkoxycarbonyl, or a (C1-C4)alkyl that is optionally substituted with one or more (e.g. 1, 2, or 3) substituents independently selected from (C1-C6)alkoxy, halo, hydroxy, cyano, nitro, tetrazole, carboxy, (C1-C6)alkoxycarbonyl, amino, methylamino, dimethylamino, or oxo (═O);
each Rb is independently Rf, ORe, —C(═O)Re, —OC(═O)Re, —C(═O)ORe, —N(Re), —NReC(═O)Rd, —C(═O)N(Re)2, —NReC(═O)ORd, —OC(═O)N(Re)2, —C(═O)N(Re)—N(Re)C(═O)Rd, —NHC(═O)NHRd, —NHS(O)0-2Rd, —S(O)0-2Rd, —OS(O)0-2Rd, —OP(═O)(ORe)2, or —P(═O)(ORe)2;
each Re is independently H or (C1-C6)alkyl;
each Rd is optionally substituted and is independently selected from (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, aryl, aryl(C1-C6)alkyl, 4-10 membered heterocyclyl and heterocyclyl(C1-C6)alkyl;
each Re is independently selected from H, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, aryl, aryl(C1-C6)alkyl, 4-10 membered heterocyclyl and heterocyclyl(C1-C6)alkyl, wherein each (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, aryl, aryl(C1-C6)alkyl, 4-10 membered heterocyclyl and heterocyclyl(C1-C6)alkyl is optionally substituted;
each Rf is optionally substituted and is independently selected from aryl and 4-10 membered heterocyclyl; and
m, p, and n are each independently 0 or 1, provided that at least one of m, p, and n is 1;
or a salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1 which is a compound of formula (Ia):
wherein:
R1 is hydrogen or 1, 2 or 3 optional substituents;
W is CRa, or N;
Ra is absent, hydrogen, or an optional substituent, and R2 is hydrogen, methyl, or fluoro; or Ra and R2 taken together are —CH2—, —CH2—CH2—, —O—, —O—CH2—, —CH2O—, —O—CH2—CH2—, or —CH2—CH2—O—;
R3 is -(Alk1)m-(Z)p-(Alk2)n-Q;
Z is —O—, —S—, —S(O)—, —SO2—, —NH—, —N(CH3)—, —N(CH2CH3)—, —C(═O)—, —OC(═O)—, —C(═O)O—, or an optionally substituted divalent monocyclic carbocycle or heterocyclic radical having 3 to 6 ring atoms, or an optionally substituted divalent bicyclic heterocyclic radical having 5 to 10 ring atoms;
Alk1 is optionally substituted (C1-C6)alkylene, (C2-C6)alkenylene, or (C1-C6)alkynylene radical, which may optionally terminate with or be interrupted by —O—, —S—, —S(O)—, —SO2—, —NH—, —N(CH3)—, —N(CH2CH3)—;
Alk2 is optionally substituted (C1-C6)alkylene, (C2-C6)alkenylene, or (C1-C6)alkynylene radical, which may optionally terminate with or be interrupted by —O—, —S—, —S(O)—, —SO2—, —NH—, —N(CH3)—, —N(CH2CH3)—;
Q is hydrogen, halo, cyano, or hydroxyl, or an optionally substituted monocyclic carbocyclic or heterocyclic radical having 3 to 7 ring atoms, or an optionally substituted bicyclic heterocyclic radical having 5 to 10 ring atoms;
the bond represented by ---- is a double bond, R4 is hydrogen, and R5 is absent; or the bond represented by ---- is a single double bond and R4 and R5 are each hydrogen;
R6 and R7 are each independently hydrogen, (C1-C6)alkyl, or benzyl, or R6 and R7 together with the nitrogen to which they are attached form a aziridino, azetidino, morpholino, thiomorpholino, piperazino, pyrrolidino or piperidino ring, which ring is optionally substituted with one or more groups independently selected from (C1-C6)alkyl; wherein any (C1-C6)alkyl of R6 and R7 is optionally substituted with one or more (e.g. 1, 2, or 3) substituents independently selected from (C1-C6)alkoxy, halo, hydroxy, cyano, nitro, amino, methylamino, dimethylamino, oxo (═O), carboxy, (C1-C6)alkoxycarbonyl, aminocarbonyl, (C1-C6)alkanoylamino, or tetrazole; and wherein any benzyl of R6 and R7 is optionally substituted with one or more (e.g. 1, 2, or 3) substituents independently selected from (C1-C6)alkyl, (C1-C6)alkoxy, halo, trifluoromethyl, trifluoromethoxy, hydroxy, cyano, nitro, tetrazole, carboxy, (C1-C6)alkoxycarbonyl, or a (C1-C4)alkyl that is optionally substituted with one or more (e.g. 1, 2, or 3) substituents independently selected from (C1-C6)alkoxy, halo, hydroxy, cyano, nitro, tetrazole, carboxy, (C1-C6)alkoxycarbonyl, amino, methylamino, dimethylamino, or oxo (═O); and
m, p, and n are each independently 0 or 1, provided that at least one of m, p, and n is 1;
or a salt thereof.

### Claim 3 (depends on 1, 2)

The compound of claim 1 or 2 which is a compound of formula (Ib):
wherein:
Rb and Rc are independently fluoro or chloro, or one of Rb and Rc is hydrogen while the other is fluoro or chloro; or a salt thereof.

### Claim 4 (depends on 1, 2)

The compound of claim 1 or 2 which is a compound of (Ic):
wherein R2 is hydrogen, methyl, or fluoro; or a salt thereof.

### Claim 5 (depends on 1, 2, 3)

The compound of any one of claims 1-3 wherein Ra and R2 are hydrogen.

### Claim 6 (depends on 1)

The compound of claim 1 wherein Ra is hydrogen or an optional substituent, R2 is hydrogen, methyl, or fluoro, and R2′ is (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C8)cycloalkyl, aryl, or 5-6 membered heterocyclyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heterocyclyl may be optionally substituted with one or more Rb.

### Claim 7 (depends on 1)

The compound of claim 1 wherein Ra is hydrogen, R2 is hydrogen, methyl, or fluoro, and R2′ is (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C8)cycloalkyl, aryl, or 5-6 membered heterocyclyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heterocyclyl may be optionally substituted with one or more Rb.

### Claim 8 (depends on 1)

The compound of claim 1 wherein Ra and R2 taken together are —CH2—, —CH2—CH2—, —O—, —O—CH2—, —CH2O—, —O—CH2—CH2—, or —CH2—CH2—O—.

### Claim 9 (depends on 1)

The compound of claim 1 wherein Ra is hydrogen or an optional substituent, and R2′ taken together with R2 is cyclopropyl, cyclobutyl, or ═CH—N(Rc)2.

### Claim 10 (depends on 1)

The compound of claim 1 wherein Ra is hydrogen, and R2′ taken together with R2 is cyclopropyl, cyclobutyl, or ═CH—N(Rc)2.

### Claim 11 (depends on 1)

The compound of claim 1 wherein Ra is hydrogen or an optional substituent, and R2′ taken together with R2 is ═CH—N(Rc)2.

### Claim 12 (depends on 1)

The compound of claim 1 wherein Ra is hydrogen, and R2′ taken together with R2 is ═CH—N(Rc)2.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound of any one of claims 1-12 wherein Z is selected from:

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound of any one of claims 1-12 wherein Z is selected from:

### Claim 15 (depends on 1, 2)

The compound of claim 1 or 2 which is a compound of (Id):
wherein:
W is CRa, or N;
Ra is hydrogen or 1, 2 or 3 optional substituents, and R2 is hydrogen, methyl, or fluoro; or Ra and R2 taken together are —CH2—, —CH2—CH2—, —O—, —O—CH2—, —CH2O—, —O—CH2—CH2—, or —CH2—CH2—O—;
Rd and Re are independently fluoro or chloro, or one of Rd and Re is hydrogen while the other is fluoro or chloro; and
R3 is a radical selected from:
in which any vacant ring position is optionally substituted;
or a salt thereof.

### Claim 16 (depends on 15)

The compound of claim 15 wherein W is CH and R2 is hydrogen.

### Claim 17 (depends on 15, 16)

The compound of claim 15 or 16 wherein Q is hydrogen or optionally substituted phenyl.

### Claim 18 (depends on 15, 16)

The compound of claim 15 or 16 wherein R3 is optionally substituted quinolin-2-yl, benzothiazol-2-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, oxadiazol-3-yl, oxadiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl or thiazolopyridin-2-yl.

### Claim 19 (depends on 18)

The compound of claim 18 wherein the optional substituents which may be present in R3 are independently selected from methyl, —OCH3, —CF3, —OCF3, ethyl, cyclopropyl, oxo, hydroxyl, fluoro, chloro, bromo, cyano, acetyl, amino, methylamino, dimethylamino, acetylamino, carbamate, —CONH2, nitro, —COOH and —CH2OH.

### Claim 20 (depends on 1)

The compound of claim 1 which is a compound of formula (Ie):
wherein:
Rb and Rc are independently fluoro or chloro, or one of Rb and Rc is hydrogen while the other is fluoro or chloro; or a salt thereof.

### Claim 21 (depends on 1)

The compound of claim 1 which is a compound of (If):
or a salt thereof.

### Claim 22 (depends on 1)

The compound of claim 1 which is a compound of (Ig):
wherein:
Rd and Re are independently fluoro or chloro, or one of Rd and Re is hydrogen while the other is fluoro or chloro; and
R3 is a radical selected from:
in which any vacant ring position is optionally substituted;
or a salt thereof.

### Claim 23 (depends on 20, 21, 22)

The compound of any one of claims 20-22 wherein R2 is hydrogen, methyl, or fluoro, and R2′ is (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C8)cycloalkyl, aryl, or 5-6 membered heterocyclyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heterocyclyl may be optionally substituted with one or more Rb.

### Claim 24 (depends on 20, 22)

The compound of claim 20 or 22 wherein Ra and R2 taken together are —CH2—, —CH2—CH2—, —O—, —O—CH2—, —CH2O—, —O—CH2—CH2—, or —CH2—CH2—O—.

### Claim 25 (depends on 20, 21, 22)

The compound of any one of claims 20-22 wherein R2′ taken together with R2 is cyclopropyl, cyclobutyl, azetidine, or ═CH—N(Rc)2; wherein the cyclopropyl, cyclobutyl, and azetidine can optionally be substituted with (C1-C6)alkyl.

### Claim 26 (depends on 1)

The compound of claim 1 wherein:
is selected from:

### Claim 27 (depends on 1)

The compound of claim 1 wherein:
is selected from:

### Claim 28 (depends on 1)

The compound of claim 1 wherein:
is selected from:

### Claim 29

A compound selected from:
and salts thereof.

### Claim 30

A compound selected from:
and salts thereof.

### Claim 31

A compound selected from:
and salts thereof.

### Claim 32

A compound selected from:
and salts thereof.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A method for treating a bacterial infection in a mammal comprising administering to the mammal an effective amount of a compound as described in any one of claims 1-32, or a pharmaceutically acceptable salt thereof.

### Claim 34 (depends on 33)

The method of claim 33 wherein the bacterial infection is a Gram-negative bacterial strain infection.

### Claim 35 (depends on 34)

The method of claim 34 wherein the Gram-negative bacterial strain is selected from the group consisting of Escherchia coli, Caulobacter crescentus, Pseudomonas aeruginosa, Agrobacterium tumefaciens, Branhamella catarrhalis, Citrobacter diversus, Enterobacter aerogenes, Enterobacter cloacae, Enterobacter sakazakii, Enterobacter asburiae, Pantoea agglomerans, Klebsiella pneumoniae, Klebsiella oxytoca, Klebsiella rhinoscleromatis, Proteus mirabilis, Salmonella typhimurium, Salmonella enteriditis, Serratia marcescens, Shigella sonnei, Neisseria gonorrhoeae, Acinetobacter baumannii, Acinetobacter calcoaceticus, Acinetobacter lwoffi, Salmonella enteriditis, Fusobacterium nucleatum, Veillonella parvula, Bacteroides forsythus, Actinobacillus actinomycetemcomitans, Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Helicobacter pylori, Francisella tularensis, Yersinia pestis, Borrelia burgdorferi, Neisseria meningitidis and Haemophilus influenzae.

### Claim 36 (depends on 33)

The method of claim 33 wherein the bacterial infection is a Gram-positive bacterial strain infection.

### Claim 37 (depends on 36)

The method of claim 36 wherein the Gram-positive bacterial strain is selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Streptococcus pyogenes, Streptococcus faecalis, Enterococcus faecalis, Enterococcus faecium, Bacillus subtilis, Micrococcus luteus, Mycobacterium tuberculosis, Bacillus anthracis, Bacillus cereus, Clostridium difficile, Propionibacterium acnes, Streptococcus mutans, Actinomyces viscosus, Actinomyces naeslundii, Streptococcus sanguis, Streptococcus pneumoniae and Streptococcus salivarius.

### Claim 38 (depends on 33)

The method of claim 33 wherein the bacterial infection is a multiple drug-resistant bacterial strain infection.

### Claim 39 (depends on 38)

The method of claim 38 wherein the multiple drug-resistance bacterial strain is selected from the group consisting of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, multiple drug-resistant tuberculosis and multidrug-resistant Clostridium difficile.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A pharmaceutical composition comprising a compound of formula I as described in any one of claims 1-32 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A compound of formula I as described in any one of claims 1-32 or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a bacterial infection.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A compound of formula I as described in any one of claims 1-32 or a pharmaceutically acceptable salt thereof for use in medical treatment.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The use of a compound of formula I as described in any one of claims 1-32 or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating a bacterial infection in a mammal.
